CDE Catalog | NINDS Common Data Elements

***Please contact the NINDS CDE Team (NINDSCDE@emmes.com) if you encounter any search difficulties.***

The CDE Catalog is a directory of the available NINDS CDEs. Users can search the Catalog to isolate a subset of the CDEs (e.g., all stroke-specific CDEs, etc.), and to view and download details about the CDEs.

Select any filter below to search the CDE Catalog.

For best results, clear form between searches. In addition, when specifying NeuroRehab, Sport-Related Concussion (SRC) or Traumatic Brain Injury (TBI) as the Disease, please select a Subdisease as well.

NeuroRehab Comprehensive includes all NeuroRehab CDE recommendations. NeuroRehab General includes all NeuroRehab CDE recommendations that are not disease specific. All other NeuroRehab Subdiseases include recommendations specific to existing NINDS CDE project disorders.

Choose your Time Frame for your SRC study (Acute (time of injury until 72 hours), Subacute (after 72 hours to 3 months), and Persistent/Chronic (3 months and greater post-concussion) or Comprehensive if your study falls across the study time frames.

Choose your type of TBI study (Acute Hospitalized, Concussion/Mild TBI, Moderate/Severe TBI: Rehabilitation, or Epidemiology) or Comprehensive if your study falls outside of the study types or incorporates aspects of more than one type of study.

Search Form

Subdomain Name

CRF Name

Displaying 701 - 725 of 755

Operations

Selected 25 rows in this page.

The search results below can be downloaded by clicking the checkboxes on the far left side of the table. Select the header checkbox to select all CDEs listed on the first page. Then choose CDE Detailed Report from the Choose an operation dropdown menu.
Select all	CDE ID	CDE Name	Definition	Classification	CRF Name	Copyrighted or trademarked	Disease Name	Subdisease Name
F0025-C01700	C01700	Specimen accession number	Number with which the specimen taken for the tests being reported was accessioned to the record storage facility	Supplemental	Laboratory Tests and Tracking	False	General (For all diseases)	General (For all diseases)
F0004-C20402	C20402	Study blind broken indicator	Indicator of whether the study blind was broken	Supplemental	Serious Adverse Events	0	General (For all diseases)	General (For all diseases)
F0022-C02019	C02019	Study drug actual return count	Count of amount of study drug returned	Supplemental	Study Drug Compliance	False	General (For all diseases)	General (For all diseases)
F0022-C02018	C02018	Study drug dispensed count	Count of amount of study drug dispensed to the participant/subject	Supplemental	Study Drug Compliance	False	General (For all diseases)	General (For all diseases)
F0022-C02004	C02004	Study drug dispensed date and time	Date (and time, if applicable and known) on which a participant/subject was given or applied a therapeutic agent (drug, intervention therapy) used in a clinical trial protocol	Supplemental	Study Drug Compliance	False	General (For all diseases)	General (For all diseases)
F0022-C02010	C02010	Study drug dosage form text	Text of dosage form used to administer study drug	Supplemental	Study Drug Compliance	False	General (For all diseases)	General (For all diseases)
F0024-C02007	C02007	Study drug dose	Dose of study drug taken per administration	Supplemental	Study Drug Dosing	False	General (For all diseases)	General (For all diseases)
F0024-C02012	C02012	Study drug dose frequency	Frequency of use of study drug	Supplemental	Study Drug Dosing	False	General (For all diseases)	General (For all diseases)
F0024-C02023	C02023	Study drug dose unit of measure	Unit of measure of the study drug dosage administered	Supplemental	Study Drug Dosing	False	General (For all diseases)	General (For all diseases)
F0024-C02026	C02026	Study drug dose unit of measure UCUM code	Code that represents the dosage unit of measure of the study drug administered	Supplemental	Study Drug Dosing	False	General (For all diseases)	General (For all diseases)
F0024-C02009	C02009	Study drug end date and time	Date (and time, if applicable and known) the administration of the study drug ended	Supplemental	Study Drug Dosing	False	General (For all diseases)	General (For all diseases)
F0022-C02020	C02020	Study drug expected returned count	Count of expected amount of study drug returned	Supplemental	Study Drug Compliance	False	General (For all diseases)	General (For all diseases)
F0022-C02021	C02021	Study drug expected taken count	Count of expected amount of study drug taken	Supplemental	Study Drug Compliance	False	General (For all diseases)	General (For all diseases)
F0022-C02005	C02005	Study drug returned date and time	Date (and time, if applicable and known) on which the study drug was returned	Supplemental	Study Drug Compliance	False	General (For all diseases)	General (For all diseases)
F0024-C02017	C02017	Study drug start date and time	Date (and time, if applicable and known) on which the study drug usage begins	Supplemental	Study Drug Dosing	False	General (For all diseases)	General (For all diseases)
F0012-C02215	C02215	Study eligibility indicator	Indicator of whether the participant/subject is eligible for participation in the clinical research protocol according to its inclusion and exclusion criteria	Supplemental	Inclusion and Exclusion Criteria	False	General (For all diseases)	General (For all diseases)
F0004-C60379	C60379	Study intervention name	Name of study intervention	Supplemental	Serious Adverse Events	0	General (For all diseases)	General (For all diseases)
F0299-C05122	C05122	Study therapy administered date and time	Date (and time, if applicable and known) the study therapy was administered to the participant/subject	Supplemental	Study Therapies Compliance	False	General (For all diseases)	General (For all diseases)
F0299-C05120	C05120	Study therapy session actual duration	Duration of the actual study therapy session in minutes	Supplemental	Study Therapies Compliance	False	General (For all diseases)	General (For all diseases)
F0299-C05123	C05123	Study therapy session expected duration	Duration expected of the study therapy session in minutes according to study protocol	Supplemental	Study Therapies Compliance	False	General (For all diseases)	General (For all diseases)
F0005-C21124	C21124	Subject email address name	The name of the email address of the subject/participant	Supplemental	Participant/Subject Contact Information	False	General (For all diseases)	General (For all diseases)
F0005-C21119	C21119	Subject home city name	Name of city in which the subject/participant lives	Supplemental	Participant/Subject Contact Information	False	General (For all diseases)	General (For all diseases)
F0005-C21122	C21122	Subject home phone number	The home phone number of the subject/participant	Supplemental	Participant/Subject Contact Information	False	General (For all diseases)	General (For all diseases)
F0005-C21120	C21120	Subject home state province name	The name of the state or province that the subject/participant inhabits	Supplemental	Participant/Subject Contact Information	False	General (For all diseases)	General (For all diseases)
F0005-C21118	C21118	Subject mailing address name	Name of the mailing address of subject/participant	Supplemental	Participant/Subject Contact Information	False	General (For all diseases)	General (For all diseases)

Displaying 701 - 725 of 755

The NINDS CDE Team does not post proprietary instruments/scales recommended by the CDE Working Groups on this website. This includes, but is not limited to, copyrighted or trademarked instruments/scales. Information about recommended instruments can be found in the Notice of Copyright (NOC) documents under ‘CRF Module/Guideline’ on each disorder’s data standards page. For any questions regarding these instruments/scales please contact the corresponding owner/author. The NINDS CDE Team is not responsible for the availability or content of these external sites, nor does the NINDS CDE Team endorse, warrant or guarantee the products, services or information described or offered at these other internet sites.